Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 73
Filter
Add more filters










Publication year range
1.
Microscopy (Oxf) ; 71(3): 152-160, 2022 Jun 06.
Article in English | MEDLINE | ID: mdl-35289919

ABSTRACT

Retinoic acid (RA) plays an important role in epithelial homeostasis and influences the morphology, proliferation, differentiation and permeability of epithelial cells. Mouse keratinocytes, K38, reconstituted non-keratinized stratified epithelium in three-dimensional (3D) cultures with serum, which contains retinol (a source of RA), but the morphology was different from in vivo epithelium. The formed epithelium was thick, with loosened cell-cell contacts. Here, we investigated whether the inhibition of RA receptor (RAR)/retinoid X receptor (RXR)-mediated signaling by an RXR antagonist, HX 531, improved K38 3D cultures in terms of morphology and intercellular junctions. The epithelium formed by 0.5 µM HX531 was thin, and the intercellular space was narrowed because of the restoration of the layer-specific distribution of desmoglein (DSG)-1, DSG3 and plakoglobin (PG). Moreover, the levels of desmosomal proteins and tight junction proteins, including DSG1, DSG2, DSG3, PG, claudin (CLDN)-1 and CLDN4 increased, but the adherens junction protein, E-cadherin, did not show any change. Furthermore, CLDN1 was recruited to occludin-positive cell-cell contacts in the superficial cells and transepithelial electrical resistance was increased. Therefore, K38 3D cultures treated with 0.5 µM HX531 provides a useful in vitro model to study intercellular junctions in the non-keratinized epithelium.


Subject(s)
Desmosomal Cadherins , Keratinocytes , Retinoid X Receptors , Animals , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Cell Culture Techniques, Three Dimensional , Desmosomal Cadherins/metabolism , Keratinocytes/cytology , Keratinocytes/drug effects , Keratinocytes/metabolism , Mice , Permeability , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/metabolism
2.
Biomolecules ; 11(10)2021 10 07.
Article in English | MEDLINE | ID: mdl-34680110

ABSTRACT

Diabetic kidney is associated with an accumulation of extracellular matrix (ECM) leading to renal fibrosis. Dysregulation of retinoic acid metabolism involving retinoic acid receptors (RARs) and retinoid X receptors (RXRs) has been shown to play a crucial role in diabetic nephropathy (DN). Furthermore, RARs and peroxisome proliferator-activated receptor γ (PPARγ) are known to control the RXR-mediated transcriptional regulation of several target genes involved in DN. Recently, RAR and RXR have been shown to upregulate plasminogen activator inhibitor-1 (PAI-1), a major player involved in ECM accumulation and renal fibrosis during DN. Interestingly, hydrogen sulfide (H2S) has been shown to ameliorate adverse renal remodeling in DN. We investigated the role of RXR signaling in the ECM turnover in diabetic kidney, and whether H2S can mitigate ECM accumulation by modulating PPAR/RAR-mediated RXR signaling. We used wild-type (C57BL/6J), diabetic (C57BL/6-Ins2Akita/J) mice and mouse mesangial cells (MCs) as experimental models. GYY4137 was used as a H2S donor. Results showed that in diabetic kidney, the expression of PPARγ was decreased, whereas upregulations of RXRα, RXRß, and RARγ1 expression were observed. The changes were associated with elevated PAI-1, MMP-9 and MMP-13. In addition, the expressions of collagen IV, fibronectin and laminin were increased, whereas elastin expression was decreased in the diabetic kidney. Excessive collagen deposition was observed predominantly in the peri-glomerular and glomerular regions of the diabetic kidney. Immunohistochemical localization revealed elevated expression of fibronectin and laminin in the glomeruli of the diabetic kidney. GYY4137 reversed the pathological changes. Similar results were observed in in vitro experiments. In conclusion, our data suggest that RXR signaling plays a significant role in ECM turnover, and GYY4137 modulates PPAR/RAR-mediated RXR signaling to ameliorate PAI-1-dependent adverse ECM turnover in DN.


Subject(s)
Diabetic Nephropathies/drug therapy , PPAR gamma/genetics , Plasminogen Activator Inhibitor 1/genetics , Retinoid X Receptors/genetics , Animals , Diabetic Nephropathies/genetics , Diabetic Nephropathies/pathology , Extracellular Matrix/drug effects , Fibrosis/drug therapy , Fibrosis/genetics , Fibrosis/pathology , Gene Expression Regulation/drug effects , Humans , Hydrogen Sulfide/pharmacology , Kidney/drug effects , Kidney/pathology , Mice , Mice, Inbred NOD , Morpholines/pharmacology , Organothiophosphorus Compounds/pharmacology , Receptors, Retinoic Acid/antagonists & inhibitors , Receptors, Retinoic Acid/genetics , Retinoid X Receptors/antagonists & inhibitors , Signal Transduction/drug effects , Tretinoin/metabolism
3.
J Mol Model ; 27(8): 231, 2021 Jul 26.
Article in English | MEDLINE | ID: mdl-34312718

ABSTRACT

The Retinoid X Receptor (RXR) is an attractive target in the treatment of colon cancer. Different therapeutic binders with high potency have been used to specifically target RXR. Among these compounds is a novel analogue of berberine, B12. We provided structural and molecular insights into the therapeutic activity properties of B12 relative to its parent compound, berberine, using force field estimations and thermodynamic calculations. Upon binding of B12 to RXR, the high instability elicited by RXR was markedly reduced; similar observation was seen in the berberine-bound RXR. However, our analysis revealed that B12 could have a more stabilizing effect on RXR when compared to berberine. Interestingly, the mechanistic behaviour of B12 in the active site of RXR opposed its impact on RXR protein. This disparity could be due to the bond formation and breaking elicited between B12/berberine and the active site residues. We observed that B12 and berberine could induce a disparate conformational change in regions Gly250-Asp258 located on the His-RXRα/LBD domain. Comparatively, the high agonistic and activation potential reported for B12 compared to berberine might be due to its superior binding affinity as evidenced in the thermodynamic estimations. The total affinity for B12 (-25.76 kcal/mol) was contributed by electrostatic interactions from Glu243 and Glu239. Also, Arg371, which plays a crucial role in the activity of RXR, formed a strong hydrogen bond with B12; however, a weak interaction was elicited between Arg371 and berberine. Taken together, our study has shown the RXRα activating potential of B12, and findings from this study could provide a framework in the future design of RXRα binders specifically tailored in the selective treatment of colon cancer.


Subject(s)
Berberine/chemistry , Colonic Neoplasms/drug therapy , Hydrogen Bonding/drug effects , Retinoid X Receptors/genetics , Berberine/analogs & derivatives , Berberine/therapeutic use , Catalytic Domain/drug effects , Colonic Neoplasms/genetics , Humans , Molecular Targeted Therapy , Protein Conformation/drug effects , Retinoid X Receptors/antagonists & inhibitors , Thermodynamics
4.
EBioMedicine ; 66: 103287, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33752129

ABSTRACT

BACKGROUND: Therapeutic agents with novel mechanisms of action are needed to combat the growing epidemic of type 2 diabetes (T2D) and related metabolic syndromes. Liver X receptor (LXR) agonists possess preclinical efficacy yet produce side effects due to excessive lipogenesis. Anticipating that many beneficial and detrimental effects of LXR agonists are mediated by ABCA1 and SREPB1c expression, respectively, we hypothesized that a phenotypic optimization strategy prioritizing selective ABCA1 induction would identify an efficacious lead compound with an improved side effect profile over existing LXRß agonists. METHODS: We synthesized and characterized a novel small molecule for selective induction of ABCA1 vs. SREBP1c in vitro. This compound was evaluated in both wild-type mice and a high-fat diet (HFD) mouse model of obesity-driven diabetes through functional, biochemical, and metabolomic analysis. FINDINGS: Six weeks of oral administration of our lead compound attenuated weight gain, glucose intolerance, insulin signaling deficits, and adiposity. Global metabolomics revealed suppression of gluconeogenesis, free fatty acids, and pro-inflammatory metabolites. Target identification linked these beneficial effects to selective LXRß agonism and PPAR/RXR antagonism. INTERPRETATION: Our observations in the HFD model, combined with the absence of lipogenesis and neutropenia in WT mice, support this novel approach to therapeutic development for T2D and related conditions.


Subject(s)
ATP Binding Cassette Transporter 1/agonists , Metabolome , Metabolomics , Obesity/etiology , Obesity/metabolism , Adiposity/drug effects , Animals , Biomarkers , Cytokines/metabolism , Diet, High-Fat , Disease Models, Animal , Disease Susceptibility , Drug Development , Glucose Intolerance , Inflammation Mediators/metabolism , Insulin Resistance , Lipids/blood , Lipogenesis , Liver X Receptors/agonists , Male , Metabolomics/methods , Mice , Molecular Targeted Therapy , Obesity/drug therapy , Peroxisome Proliferator-Activated Receptors/antagonists & inhibitors , RNA, Small Interfering/genetics , Retinoid X Receptors/antagonists & inhibitors
5.
J Med Chem ; 64(1): 861-870, 2021 01 14.
Article in English | MEDLINE | ID: mdl-33378197

ABSTRACT

Retinoid X receptor (RXR) modulators (rexinoids) are considered to have therapeutic potential for multiple diseases, such as Alzheimer's disease and Parkinson's disease. To overcome various disadvantages of prior screening methods, we previously developed an RXR binding assay using a fluorescent RXR ligand, CU-6PMN (4). However, this ligand binds not only at the ligand-binding domain (LBD) but also at the dimer-dimer interface of hRXRα. Here, we present a new fluorescent RXR antagonist 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(11-oxo-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxamido)phenyl)amino]nicotinic acid (NEt-C343, 7), which emits strong fluorescence only when bound to the RXR-LBD. It allows us to perform a rapid, simple, and nonhazardous binding assay that does not require bound/free separation and uses a standard plate reader. The obtained Ki values of known compounds were correlated with the Ki values obtained using the standard [3H]9cis-retinoic acid assay. This assay should be useful for drug discovery as well as for research on endocrine disruptors, functional foods, and natural products.


Subject(s)
Niacin/chemistry , Retinoid X Receptors/antagonists & inhibitors , Binding Sites , Humans , Kinetics , Ligands , Molecular Docking Simulation , Niacin/metabolism , Niacin/pharmacology , Protein Binding , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Spectrometry, Fluorescence , Transcriptional Activation/drug effects
6.
J Med Chem ; 64(1): 430-439, 2021 01 14.
Article in English | MEDLINE | ID: mdl-33356247

ABSTRACT

Retinoid X receptor (RXR) heterodimers such as PPAR/RXR, LXR/RXR, and FXR/RXR can be activated by RXR agonists alone and are therefore designated as permissive. Similarly, existing RXR antagonists show allosteric antagonism toward partner receptor agonists in these permissive RXR heterodimers. Here, we show 1-(3-(2-ethoxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(trifluoromethyl)-1H-benzo[d]imidazole-5-carboxylic acid (14, CBTF-EE) as the first RXR antagonist that does not show allosteric inhibition in permissive RXR heterodimers. This compound was designed based on the hypothesis that RXR antagonists that do not induce conformational changes of RXR would not exhibit such allosteric inhibition. CD spectra and X-ray co-crystallography of the complex of 14 and the RXR ligand binding domain (LBD) confirmed that 14 does not change the conformation of hRXR-LBD. The X-ray structure analysis revealed that 14 binds at the entrance of the ligand binding pocket (LBP), blocking access to the LBP and thus serving as a "gatekeeper".


Subject(s)
Retinoid X Receptors/antagonists & inhibitors , Allosteric Regulation , Circular Dichroism , Crystallography, X-Ray , Dimerization , Ligands , Retinoid X Receptors/chemistry
7.
ChemMedChem ; 16(7): 1088-1092, 2021 04 08.
Article in English | MEDLINE | ID: mdl-33283450

ABSTRACT

Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment-based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment-based multiple ligand discovery, we have employed a large fragment library for comprehensive screening on five targets chosen from proteins for which multitarget ligands have been successfully developed previously (soluble epoxide hydrolase, leukotriene A4 hydrolase, 5-lipoxygenase, retinoid X receptor, farnesoid X receptor). Differential scanning fluorimetry served as primary screening method before fragments hitting at least two targets were validated in orthogonal assays. Thereby, we obtained valuable fragment leads with dual-target engagement for six out of ten target combinations. Our results demonstrate the applicability of fragment-based approaches to identify starting points for polypharmacological compound development with certain limitations.


Subject(s)
Drug Design , Enzyme Inhibitors/pharmacology , Arachidonate 5-Lipoxygenase/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Epoxide Hydrolases/antagonists & inhibitors , Epoxide Hydrolases/metabolism , Humans , Molecular Structure , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/metabolism , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/metabolism , Structure-Activity Relationship
8.
Bioorg Med Chem Lett ; 31: 127666, 2021 01 01.
Article in English | MEDLINE | ID: mdl-33152377

ABSTRACT

Ligands of retinoid X receptors (RXRs) are effective against various diseases, so there is a need for efficient screening methods to discover new ligands. Existing screening methods are complex and time-consuming, and a simple fluorescence assay would be highly desirable. Here, we focused on NEt-SB (4), which has a stilbene structure, as a candidate for this purpose, and examined its fluorescence properties in detail. The fluorescence intensity of 4 was remarkably increased in highly viscous solvents and upon binding to hRXRα-LBD, due to suppression of free rotation of the stilbene moiety. Although the relatively low fluorescence intensity and the short fluorescence wavelength of 4 make this compound itself unsuitable for use in RXR binding assay, our findings provide a basis for further structural evolution, which may lead to a derivative that would be suitable for fluorescence assay of RXR binders.


Subject(s)
Fluorescence , Retinoid X Receptors/antagonists & inhibitors , Stilbenes/pharmacology , Dose-Response Relationship, Drug , Humans , Ligands , Molecular Structure , Spectrometry, Fluorescence , Stilbenes/chemistry , Structure-Activity Relationship
9.
Psychopharmacology (Berl) ; 237(7): 2055-2073, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32472163

ABSTRACT

RATIONALE: The nuclear receptor retinoid X receptor (RXR) belongs to a nuclear receptor superfamily that modulates diverse functions via homodimerization with itself or several other nuclear receptors, including PPARα. While the activation of PPARα by natural or synthetic agonists regulates the sleep-wake cycle, the role of RXR in the sleep modulation is unknown. OBJECTIVES: We investigated the effects of bexarotene (Bexa, a RXR agonist) or UVI 3003 (UVI, a RXR antagonist) on sleep, sleep homeostasis, levels of neurochemical related to sleep modulation, and c-Fos and NeuN expression. METHODS: The sleep-wake cycle and sleep homeostasis were analyzed after application of Bexa or UVI. Moreover, we also evaluated whether Bexa or UVI could induce effects on dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine contents, collected from either the nucleus accumbens or basal forebrain. In addition, c-Fos and NeuN expression in the hypothalamus was determined after Bexa or UVI treatments. RESULTS: Systemic application of Bexa (1 mM, i.p.) attenuated slow-wave sleep and rapid eye movement sleep. In addition, Bexa increased the levels of dopamine, serotonin, norepinephrine epinephrine, adenosine, and acetylcholine sampled from either the nucleus accumbens or basal forebrain. Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity. Remarkably, UVI 3003 (1 mM, i.p.) induced opposite effects in sleep, sleep homeostasis, neurochemicals levels, and c-Fos and NeuN activity. CONCLUSIONS: The administration of RXR agonist or antagonist significantly impaired the sleep-wake cycle and exerted effects on the levels of neurochemicals related to sleep modulation. Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus. Our findings highlight the neurobiological role of RXR on sleep modulation.


Subject(s)
Bexarotene/pharmacology , Coumaric Acids/pharmacology , Retinoid X Receptors/metabolism , Sleep Stages/drug effects , Sleep Stages/physiology , Tetrahydronaphthalenes/pharmacology , Animals , Male , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Rats , Rats, Wistar , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/metabolism , Retinoid X Receptors/agonists , Retinoid X Receptors/antagonists & inhibitors
10.
Int J Mol Med ; 44(6): 2003-2014, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31638178

ABSTRACT

In the present study, we examined the function of microRNA (miR)­146a­5p in patients with refractory Mycoplasma pneumoniae pneumonia. In brief, the expression of miR­146a­5p was reduced in patients with refractory Mycoplasma pneumoniae pneumonia. Downregulation of miR­146a­5p reduced inflammation in an in vitro model of refractory Mycoplasma pneumoniae pneumonia, whilst overexpression of miR­146a­5p promoted inflammation. Downregulation of miR­146a­5p induced the protein expression of ATP­binding cassette subfamily G member 1 (ABCG1) and interleukin 1 receptor­associated kinase 1 (IRAK­1), while suppressed expression was observed of the aforementioned proteins following overexpression of miR­146a­5p in an in vitro model of refractory Mycoplasma pneumoniae pneumonia. The administration of small interfering RNA against RXR or IRAK­1 attenuated the effects of miR­146a­5p on inflammation in an in vitro model of refractory Mycoplasma pneumoniae pneumonia. Collectively, these results suggested that miR­146a­5p reduced ABCG1 expression in refractory Mycoplasma pneumoniae pneumonia via downregulation of IRAK­1.


Subject(s)
ATP Binding Cassette Transporter, Subfamily G, Member 1/genetics , Interleukin-1 Receptor-Associated Kinases/genetics , MicroRNAs/genetics , Mycoplasma pneumoniae/genetics , Pneumonia, Mycoplasma/genetics , A549 Cells , Child , Child, Preschool , Female , Gene Expression Regulation/genetics , Humans , Infant , Inflammation/genetics , Inflammation/microbiology , Inflammation/pathology , Male , MicroRNAs/pharmacology , Mycoplasma pneumoniae/pathogenicity , Pneumonia, Mycoplasma/microbiology , Pneumonia, Mycoplasma/pathology , RNA, Small Interfering/genetics , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/genetics
11.
Int J Mol Sci ; 19(8)2018 Aug 10.
Article in English | MEDLINE | ID: mdl-30103423

ABSTRACT

Retinoid X receptor (RXR) antagonists are not only useful as chemical tools for biological research, but are also candidate drugs for the treatment of various diseases, including diabetes and allergies, although no RXR antagonist has yet been approved for clinical use. In this review, we present a brief overview of RXR structure, function, and target genes, and describe currently available RXR antagonists, their structural classification, and their evaluation, focusing on the latest research.


Subject(s)
Diabetes Mellitus , Hypersensitivity , Retinoid X Receptors/antagonists & inhibitors , Animals , Diabetes Mellitus/drug therapy , Diabetes Mellitus/metabolism , Humans , Hypersensitivity/drug therapy , Hypersensitivity/metabolism
12.
Article in English | MEDLINE | ID: mdl-30153482

ABSTRACT

The objective of this study was to provide evidence of the validity of utilizing pigs as a model to study the regulation of human CYP3A4, with special emphasis on drug-drug interactions. We determined the mRNA expression and distribution of CYP3A and metabolic nuclear receptors in different tissues isolated from landrace pigs. Our results showed that CYP3A and metabolic nuclear receptor mRNAs were most highly expressed in liver tissues. The expression of the metabolic nuclear receptor pregnane X receptor (PXR) had a significant correlation with expression of CYP3A29, an analog of human CYP3A4. The correlation between their transcriptional levels was further demonstrated using LPS and TNF-α. The mRNA and protein expression of CYP3A29 and PXR in HepLi cells was significantly reduced by LPS and TNF-α treatment. CYP3A29 promoter activity was dramatically elevated by PXR over expression, whereas LPS and TNF-α treatment inhibited the enhanced CYP3A29 promoter activity that was induced by PXR; presumably through inhibition of PXR promoter activity. Furthermore, the inhibition of CYP3A29 promoter activity by LPS and TNF-α treatment was blocked by knockdown of PXR or retinoid X receptor (RXR). These data suggest high similarity in the regulation mechanism of pig CYP3A29 and human CYP3A4. Our research provided a significant evaluation to determine whether pigs are suitable as an experimental animal model.


Subject(s)
Cytochrome P-450 CYP3A/metabolism , Gene Expression Regulation, Developmental , Hepatocytes/enzymology , Promoter Regions, Genetic , Receptors, Steroid/metabolism , Animals , Animals, Inbred Strains , Cell Line , China , Cytochrome P-450 CYP3A/chemistry , Cytochrome P-450 CYP3A/genetics , Gene Expression Regulation, Developmental/drug effects , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Ligands , Lipopolysaccharides/pharmacology , Male , Orchiectomy/veterinary , Organ Specificity , Pregnane X Receptor , Promoter Regions, Genetic/drug effects , RNA Interference , Receptors, Steroid/antagonists & inhibitors , Receptors, Steroid/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Sequence Homology, Amino Acid , Species Specificity , Sus scrofa , Tumor Necrosis Factor-alpha/metabolism
13.
Sci Rep ; 8(1): 7238, 2018 05 08.
Article in English | MEDLINE | ID: mdl-29740162

ABSTRACT

Increasing evidence has shown that Chinese herbal medicine (CHM) has promising therapeutic effects in colorectal cancer (CRC); however, the active ingredients and potential targets remain unclear. In this study, we aimed to investigate the relative molecular targets of the Chinese herbs that have been found effective in treating metastatic CRC (mCRC) based on clinical data and network pharmacology. In multivariate analysis CHM resulted an independent prognostic factor. The hazard ratio was 0.103 (95% confidence interval = 0.064-0.164; P < 0.001). Compared with the non-CHM group, the median survival time of the CHM group was also improved (40 versus 12 months; P < 0.001). Eighteen out of 295 herbs showed significant correlation with survival results (P < 0.05). Bioinformatics analysis indicated that the 18 herbs realize anti-CRC activity mainly through suppressing the proliferative activity of ERBB2, peroxisome proliferator-activated receptor gamma, and retinoid X receptor, suppressing angiogenesis via inhibition of VEGFR and VEGFA expression, inhibiting the phosphatidylinositol-3-kinase/AKT1 signaling pathway directly through SRC and AKT1, and reducing tumor necrosis factor-induced inflammation.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Colorectal Neoplasms/drug therapy , Drugs, Chinese Herbal/therapeutic use , Gene Expression Regulation, Neoplastic/drug effects , Gene Regulatory Networks/drug effects , Neovascularization, Pathologic/prevention & control , Adult , Aged , Colorectal Neoplasms/genetics , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Computational Biology , Female , Humans , Lymphatic Metastasis , Male , Medicine, Chinese Traditional/methods , Middle Aged , Molecular Targeted Therapy , Multivariate Analysis , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/metabolism , PPAR gamma/antagonists & inhibitors , PPAR gamma/genetics , PPAR gamma/metabolism , Phosphatidylinositol 3-Kinase/genetics , Phosphatidylinositol 3-Kinase/metabolism , Phosphoinositide-3 Kinase Inhibitors , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor/genetics , Receptors, Vascular Endothelial Growth Factor/metabolism , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Retrospective Studies , Signal Transduction , Survival Analysis , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , src-Family Kinases/antagonists & inhibitors , src-Family Kinases/genetics , src-Family Kinases/metabolism
14.
Immunol Lett ; 196: 68-73, 2018 04.
Article in English | MEDLINE | ID: mdl-29410064

ABSTRACT

Active metabolites of vitamin A, retinoic acids (RAs), are known to play critical roles in mucosal immune responses and dramatically inhibit human eosinophil apoptosis, but the detailed mechanisms have not been elucidated. We previously screened for ICAM-1 (CD54) upregulation in RA-stimulated human eosinophils by gene microarray analysis. As ICAM-1 induction and activation were observed to have a role in maintenance of eosinophil survival, we tested the hypothesis that RAs prolong eosinophil survival through ICAM-1 outside-in signaling. Blood-derived isolated eosinophils cultured with 9-cis RA and all-trans RA showed significant upregulation of ICAM-1 mRNA and cell surface expression. TTNPB, a retinoic acid receptor agonist, also induced ICAM-1 expression, while HX630, a retinoid X receptor agonist, did not. Furthermore, an RAR antagonist, HX531, completely inhibited the effect of RAs. Upregulated ICAM-1 was associated with altered kinetics of Akt, ERK, and p38 MAP kinase phosphorylation through ICAM-1 cross-linking, but an ICAM-1-blocking antibody did not affect RA-mediated cell survival. These findings indicate that RAs induce functional ICAM-1 expression through RARs, but the induced ICAM-1 does not contribute to prolongation of eosinophil survival.


Subject(s)
Eosinophils/drug effects , Intercellular Adhesion Molecule-1/metabolism , Tretinoin/pharmacology , Up-Regulation/drug effects , Apoptosis/drug effects , Apoptosis/genetics , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Cell Survival/drug effects , Cell Survival/genetics , Cells, Cultured , Eosinophils/cytology , Eosinophils/metabolism , Gene Expression/drug effects , Humans , Intercellular Adhesion Molecule-1/genetics , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics
15.
J Neuroinflammation ; 15(1): 43, 2018 Feb 15.
Article in English | MEDLINE | ID: mdl-29448961

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is a highly prevalent neurodegenerative disorder characterized by pathological hallmarks of beta-amyloid plaque deposits, tau pathology, inflammation, and cognitive decline. Treatment remains a clinical obstacle due to lack of effective therapeutics. Agonists targeting nuclear receptors, such as bexarotene, reversed cognitive deficits regardless of treatment duration and age in murine models of AD. While bexarotene demonstrated marked efficacy in decreasing plaque levels following short-term treatment, prolonged treatment did not modulate plaque burden. This suggested that plaques might reform in mice treated chronically with bexarotene and that cessation of bexarotene treatment before plaques reform might alter amyloid pathology, inflammation, and cognition in AD mice. METHODS: We utilized one-year-old APP/PS1 mice that were divided into two groups. We treated one group of mice for 2 weeks with bexarotene. The other group of mice was treated for 2 weeks with bexarotene followed by withdrawal of drug treatment for an additional 2 weeks. Cognition was evaluated using the novel-object recognition test either at the end of bexarotene treatment or the end of the withdrawal period. We then analyzed amyloid pathology and microgliosis at the conclusion of the study in both groups. RESULTS: Bexarotene treatment enhanced cognition in APP/PS1 mice similar to previous findings. Strikingly, we observed sustained cognitive improvements in mice in which bexarotene treatment was discontinued for 2 weeks. We observed a sustained reduction in microgliosis and plaque burden following drug withdrawal exclusively in the hippocampus. CONCLUSIONS: Our findings demonstrate that bexarotene selectively modifies aspects of neuroinflammation in a region-specific manner to reverse hippocampal-dependent cognitive deficits in AD mice and may provide insight to inform future studies with nuclear receptor agonists.


Subject(s)
Alzheimer Disease/drug therapy , Bexarotene/therapeutic use , Cognition Disorders/drug therapy , Disease Models, Animal , Plaque, Amyloid/drug therapy , Retinoid X Receptors/agonists , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/analysis , Animals , Animals, Newborn , Bexarotene/pharmacology , Cells, Cultured , Cognition/drug effects , Cognition/physiology , Cognition Disorders/metabolism , Cognition Disorders/pathology , Female , Humans , Male , Mice , Mice, Transgenic , Peptide Fragments/analysis , Plaque, Amyloid/metabolism , Plaque, Amyloid/pathology , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/metabolism , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/metabolism
16.
Arch Physiol Biochem ; 124(2): 131-138, 2018 May.
Article in English | MEDLINE | ID: mdl-28857622

ABSTRACT

CONTEXT: Molecular pathogenesis of chronic alcoholism is linked to increased endoplasmic reticulum stress. Ethanol is a competitive inhibitor of vitamin A metabolism and vitamin A supplementation aggravates existing liver problems. Hence, we probed into the impact of supplementation of all trans retinoic acid (ATRA), the active metabolite of vitamin A on ethanol-induced endoplasmic reticulcum stress. METHODS: Male Sprague-Dawley rats were divided into four groups - I: Control; II: Ethanol; III: ATRA; IV: ATRA + Ethanol. After 90 days the animals were sacrificed to study markers of lipid peroxidation in hepatic microsomal fraction and expression of ER stress proteins and apoptosis in liver. RESULTS AND CONCLUSION: Ethanol caused hepatic hyperlipidemia, enhanced microsomal lipid peroxidation, upregulated expression of unfolded protein response associated proteins and that of apoptosis. Ethanol also led to downregulation of retinoid receptors. ATRA supplementation reversed all these alterations indicating the decrease in ethanol-induced endoplasmic reticulum stress.


Subject(s)
Dietary Supplements , Endoplasmic Reticulum Stress , Fatty Liver, Alcoholic/prevention & control , Liver/metabolism , Protective Agents/therapeutic use , Receptors, Retinoic Acid/agonists , Tretinoin/therapeutic use , Activating Transcription Factor 4/agonists , Activating Transcription Factor 4/antagonists & inhibitors , Activating Transcription Factor 4/genetics , Activating Transcription Factor 4/metabolism , Animals , Apoptosis/drug effects , Biomarkers/metabolism , Cytochrome P-450 CYP2E1/chemistry , Cytochrome P-450 CYP2E1/genetics , Cytochrome P-450 CYP2E1/metabolism , Endoplasmic Reticulum Stress/drug effects , Ethanol/toxicity , Fatty Liver, Alcoholic/enzymology , Fatty Liver, Alcoholic/metabolism , Gene Expression Regulation/drug effects , Lipid Metabolism/drug effects , Lipid Peroxidation/drug effects , Liver/drug effects , Liver/enzymology , Male , Rats, Sprague-Dawley , Receptors, Retinoic Acid/antagonists & inhibitors , Receptors, Retinoic Acid/genetics , Receptors, Retinoic Acid/metabolism , Retinoid X Receptors/agonists , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/genetics , Retinoid X Receptors/metabolism , Transcription Factor CHOP/agonists , Transcription Factor CHOP/antagonists & inhibitors , Transcription Factor CHOP/genetics , Transcription Factor CHOP/metabolism , Tretinoin/antagonists & inhibitors , Unfolded Protein Response/drug effects , X-Box Binding Protein 1/agonists , X-Box Binding Protein 1/antagonists & inhibitors , X-Box Binding Protein 1/genetics , X-Box Binding Protein 1/metabolism
17.
Mol Neurobiol ; 55(6): 5059-5074, 2018 Jun.
Article in English | MEDLINE | ID: mdl-28815487

ABSTRACT

Benzophenone-3 (BP-3) is the most widely used compound among UV filters for the prevention of photodegradation. Population studies have demonstrated that it penetrates through the skin and crosses the blood-brain barrier. However, little is known about the impact of BP-3 on the nervous system and its possible adverse effects on the developing brain. We demonstrated that the neurotoxic effects of BP-3 were accompanied by the induction of apoptosis, as evidenced by apoptosis-related caspase-3 activation and apoptotic body formation as well as the inhibition of autophagy, as determined by the downregulation of autophagy-related genes, decreased autophagosome formation, and reduced LC3B-to-LC3A ratio. In this study, we showed for the first time that the BP-3-induced apoptosis of neuronal cells is mediated via the stimulation of RXRα signaling and the attenuation of RXRß/RXRγ signaling, as demonstrated using selective antagonist and specific siRNAs as well as by measuring the mRNA and protein expression levels of the receptors. This study also demonstrated that environmentally relevant concentrations of BP-3 were able to inhibit autophagy and disrupt the epigenetic status of neuronal cells, as evidenced by the inhibition of global DNA methylation as well as the reduction of histone deacetylases and histone acetyl transferases activity, which may increase the risks of neurodevelopmental abnormalities and/or neural degenerations.


Subject(s)
Apoptosis/drug effects , Autophagy/drug effects , Benzophenones/pharmacology , Epigenesis, Genetic/drug effects , Neurons/cytology , Neurons/metabolism , Retinoid X Receptors/metabolism , Signal Transduction/drug effects , Animals , Apoptosis/genetics , Autophagy/genetics , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Caspase 3/metabolism , Cells, Cultured , DNA Methylation/drug effects , Gene Expression Profiling , Histone Acetyltransferases/metabolism , Histone Deacetylases/metabolism , L-Lactate Dehydrogenase/metabolism , Mice , Microtubule-Associated Proteins/metabolism , Neocortex/cytology , Neurons/drug effects , Phagosomes/drug effects , Phagosomes/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/metabolism , Retinoid X Receptors/agonists , Retinoid X Receptors/antagonists & inhibitors , Retinoid X Receptors/genetics , Staining and Labeling , Time Factors
18.
PLoS One ; 12(8): e0181055, 2017.
Article in English | MEDLINE | ID: mdl-28800627

ABSTRACT

The effects of retinoids on adrenal aldosterone synthase gene (CYP11B2) expression and aldosterone secretion are still unknown. We therefore examined the effects of nuclear retinoid X receptor (RXR) pan-agonist PA024 on CYP11B2 expression, aldosterone secretion and blood pressure, to elucidate its potential as a novel anti-hypertensive drug. We demonstrated that PA024 significantly suppressed angiotensin II (Ang II)-induced CYP11B2 mRNA expression, promoter activity and aldosterone secretion in human adrenocortical H295R cells. Human CYP11B2 promoter functional analyses using its deletion and point mutants indicated that the suppression of CYP11B2 promoter activity by PA024 was in the region from -1521 (full length) to -106 including the NBRE-1 and the Ad5 elements, and the Ad5 element may be mainly involved in the PA024-mediated suppression. PA024 also significantly suppressed the Ang II-induced mRNA expression of transcription factors NURR1 and NGFIB that bind to and activate the Ad5 element. NURR1 overexpression demonstrated that the decrease of NURR1 expression may contribute to the PA024-mediated suppression of CYP11B2 transcription. PA024 also suppressed the Ang II-induced mRNA expression of StAR, HSD3ß2 and CYP21A2, a steroidogenic enzyme group involved in aldosterone biosynthesis. Additionally, the PA024-mediated CYP11B2 transcription suppression was shown to be exerted via RXRα. Moreover, the combination of PPARγ agonist pioglitazone and PA024 caused synergistic suppressive effects on CYP11B2 mRNA expression. Finally, PA024 treatment significantly lowered both the systolic and diastolic blood pressure in Tsukuba hypertensive mice (hRN8-12 x hAG2-5). Thus, RXR pan-agonist PA024 may be a candidate anti-hypertensive drugs that acts via the suppression of aldosterone synthesis and secretion.


Subject(s)
2-Naphthylamine/analogs & derivatives , Adrenal Cortex/metabolism , Aldosterone/metabolism , Blood Pressure/drug effects , Cytochrome P-450 CYP11B2/metabolism , Pyrimidines/pharmacology , Retinoid X Receptors/antagonists & inhibitors , 2-Naphthylamine/pharmacology , Adrenal Cortex/drug effects , Animals , Apoptosis/drug effects , Body Weight/drug effects , Calcium/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cytochrome P-450 CYP11B2/genetics , Heart Rate/drug effects , Humans , Hydrocortisone/metabolism , Ions , Mice, Transgenic , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Pioglitazone , Point Mutation/genetics , Promoter Regions, Genetic , RNA, Messenger/genetics , RNA, Messenger/metabolism , Retinoid X Receptors/metabolism , Sequence Deletion/genetics , Steroids/biosynthesis , Thiazolidinediones/pharmacology
19.
J Comput Aided Mol Des ; 31(6): 577-585, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28534193

ABSTRACT

HX531, which contains a dibenzodiazepine skeleton, is one of the first retinoid X receptor (RXR) antagonists. Functioning via RXR-PPARγ heterodimer, this compound is receiving a lot of attention as a therapeutic drug candidate for diabetic disease controlling differentiation of adipose tissue. However, the active conformation of HX531 for RXRs is not well established. In the present study, quantum mechanics calculations and molecular mechanical docking simulations were carried out to precisely study the docking mode of HX531 with the human RXRα ligand-binding domain, as well as to provide a new approach to drug design using a structure-based perspective. It was suggested that HX531, which has the R configuration for the bent dibenzodiazepine plane together with the equatorial configuration for the N-methyl group attached to the nitrogen atom in the seven-membered diazepine ring, is a typical activation function-2 (AF-2) fixed motif perturbation type antagonist, which destabilizes the formation of AF-2 fixed motifs. On the other hand, the docking simulations supported the experimental result that LG100754 is an RXR homodimer antagonist and an RXR heterodimer agonist.


Subject(s)
Benzoates/chemistry , Biphenyl Compounds/chemistry , Retinoid X Receptors/agonists , Retinoid X Receptors/antagonists & inhibitors , Retinoids/chemistry , Tetrahydronaphthalenes/chemistry , Amino Acid Motifs , Binding Sites , Humans , Molecular Docking Simulation , PPAR gamma/agonists , PPAR gamma/chemistry , Protein Binding , Protein Conformation , Protein Domains , Protein Multimerization , Quantum Theory , Retinoid X Receptors/chemistry , Stereoisomerism , Structure-Activity Relationship
20.
Toxicol Appl Pharmacol ; 314: 91-97, 2017 Jan 01.
Article in English | MEDLINE | ID: mdl-27894914

ABSTRACT

The RXR agonist (triphenyltin, TPT) and the RXR antagonist (UVI3003) both show teratogenicity and, unexpectedly, induce similar malformations in Xenopus tropicalis embryos. In the present study, we exposed X. tropicalis embryos to UVI3003 in seven specific developmental windows and identified changes in gene expression. We further measured the ability of UVI3003 to activate Xenopus RXRα (xRXRα) and PPARγ (xPPARγ) in vitro and in vivo. We found that UVI3003 activated xPPARγ either in Cos7 cells (in vitro) or Xenopus embryos (in vivo). UVI3003 did not significantly activate human or mouse PPARγ in vitro; therefore, the activation of Xenopus PPARγ by UVI3003 is novel. The ability of UVI3003 to activate xPPARγ explains why UVI3003 and TPT yield similar phenotypes in Xenopus embryos. Our results indicate that activating PPARγ leads to teratogenic effects in Xenopus embryos. More generally, we infer that chemicals known to specifically modulate mammalian nuclear hormone receptors cannot be assumed to have the same activity in non-mammalian species, such as Xenopus. Rather they must be tested for activity and specificity on receptors of the species in question to avoid making inappropriate conclusions.


Subject(s)
Coumaric Acids/toxicity , PPAR gamma/metabolism , Retinoid X Receptors/antagonists & inhibitors , Teratogens/toxicity , Tetrahydronaphthalenes/toxicity , Xenopus/metabolism , Abnormalities, Drug-Induced , Animals , Xenopus/embryology
SELECTION OF CITATIONS
SEARCH DETAIL
...